Translational Development Acquisition Corp.
TDAC
$10.17
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 133.40K | 61.30K | 800.00 | 800.00 | 483.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.40K | 61.30K | 800.00 | 800.00 | 483.80K |
| Operating Income | -133.40K | -61.30K | -800.00 | -800.00 | -483.80K |
| Income Before Tax | -8.00K | -61.30K | -800.00 | -800.00 | -483.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.00K | -61.30K | -800.00 | -800.00 | -483.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.00K | -61.30K | -800.00 | -800.00 | -483.80K |
| EBIT | -133.40K | -61.30K | -800.00 | -800.00 | -483.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | -0.02 | 0.00 | 0.00 | -0.12 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | 0.00 | -0.07 |
| EPS Diluted | 0.00 | -0.02 | 0.00 | 0.00 | -0.12 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | 0.00 | -0.07 |
| Average Basic Shares Outstanding | 5.42M | 4.05M | 4.05M | 4.05M | 4.05M |
| Average Diluted Shares Outstanding | 5.42M | 4.05M | 4.05M | 4.05M | 4.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |